Adverse effects of tirzepatide are similar to GLP-1 RAs
Driven by the new drug approvals (for different applications), and extensive R&D efforts of the companies (to enhance delivery mechanisms of GLP-1 drugs), the market is anticipated to witness steady growth in the coming decade
doi: 10.14336/AD.2021.1006
The non-GLP-1 alternatives matter for patients who cannot tolerate GLP-1s or do not meet eligibility, a unique hedge
These higher dosages are possible to achieve in mice, since they cannot complain to scientists about side effects occurring at high dosages and do not have the physical capability to prevent themselves from receiving drug injections) Sanofi produced a triple agonist , SAR441255, which was capable of decreasing body weight in mice by around 14% at 26 days, 12% in monkeys by 42 days [34] , although Sanofi have since discontinued development of the triple agonist for human use for uncited reasons
[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Johnston E.A., Petersen K.S., Beasley J.M., Krussig T., Mitchell D.C., Van Horn L.V., Weiss R., Kris-Etherton P.M